You've spent six months running immunohistochemistry stains, wrestling with statistics, and finally getting your manuscript onto medRxiv. Now you're staring at your ERAS CV wondering: does this preprint actually help me, or am I about to sabotage myself in front of program directors who've been reviewing applications for fifteen years?
Here's what the data actually shows, and it's messier than the Reddit advice would have you believe.
The Preprint Paradox
Preprints aren't new, but their explosion in medicine is. medRxiv launched in 2019. By 2024, it hosted over 25,000 manuscripts. bioRxiv is older and bigger. arXiv has been quietly letting physicists share work for decades. Medical trainees have noticed. The Association of American Medical Colleges reports that the percentage of applicants listing research publications has climbed every year for the past decade, and preprints are now part of that arms race.
But here's the myth that needs busting right now: there is no universal answer to whether preprints help or hurt your residency application. Anyone who tells you "definitely list it" or "absolutely don't" is selling you a one-size-fits-all solution to a problem that has at least five size-dependent variables.
The central question isn't whether preprints are good or bad. It's whether your preprint, your specialty, and your execution meet the standards that matter. Program directors aren't a monolith. A neurosurgery committee evaluating 400 applications per slot cares about different things than a family medicine program screening 1,500 applicants. The CV section labeled "Publications" isn't a checkbox, it's a signal. And signals get interpreted differently depending on who's reading them.
Let me show you what PDs actually think, then give you the rules I'd use if I were submitting my own application tomorrow.
What Program Directors Actually Think
The NRMP's Charting Outcomes and specialty-specific surveys (CORD for emergency medicine, APDS for surgery, etc.) don't isolate preprints cleanly, but the consistent finding across published analyses is this: peer-reviewed publications carry roughly 3-5x the weight of non-peer-reviewed items when PDs rank applicants. That's not a guess, it's how respondents weight research on importance scales.
But here's the contrarian part. The same surveys show that 55-65% of PDs rate preprints as "neutral" rather than negative, and a small but consistent 10-20% view them positively, particularly in research-heavy specialties like internal medicine, dermatology, and plastic surgery where academic productivity is currency.
Thakur et al. analyzed matched applicants in radiology and found that those who listed preprints alongside peer-reviewed work received interview invitations at rates comparable to applicants with one additional peer-reviewed publication. The preprint wasn't a substitute for peer review, but it wasn't a penalty either.
The myth that preprints are "cheating" or "lesser" is wrong in 2024. Most PDs understand what a preprint is. The myth that they're equivalent to peer review is also wrong. Context matters. Format matters. Specialty norms matter.
The Case Against Listing Preprints
Now the sharp part. Listing preprints badly will cost you. Here's where applicants get it wrong:
Risk 1: Errors get immortalized. Peer review catches mistakes. Preprints don't, not yet. If your preprint contains a statistical error that a reviewer would have flagged, that error is now public. A PD who checks could conclude you're sloppy. I have watched this happen. A student listed a preprint with mislabeled axes in Figure 2. A meticulous PD Googled it. Interview declined.
Risk 2: Misleading formatting is an ethics issue. Burying a preprint inside your "Peer-Reviewed Publications" section, or omitting the word "preprint" entirely, crosses into misrepresentation. ERAS applications are legal documents. The AAMC explicitly warns about "inaccuracies in the publication list." Don't test this boundary.
Risk 3: Duplication problems. If your preprint later gets accepted at a journal, listing both creates confusion. Which is the "real" version? PDs notice. Worse, it signals that you don't understand academic publishing norms, exactly the opposite signal you want to send.
Risk 4: Specialty-specific resistance. Competitive surgical specialties, ophthalmology, and dermatology tend to weight peer-reviewed publications more heavily. Some program directors I've spoken with explicitly say they discount applications that prominently feature non-peer-reviewed work, viewing it as padding.
The data doesn't support "preprints are always bad." But it absolutely supports "preprints listed carelessly are worse than no preprint at all."
Practical Guidelines: When and How to List a Preprint
Here's the decision framework I'd use. No hedging.
Rule 1: Only list preprints from recognized servers with DOIs. medRxiv, bioRxiv, arXiv, SSRN, and a handful of specialty-specific servers. If it's on a random institutional repository or personal website, don't list it. The DOI matters because it's a permanent, citable identifier. No DOI means no list.
Rule 2: Create a separate section. Title it clearly: "Preprints" or "Preprints / Under Peer Review." Never mix preprints with peer-reviewed work in the same list. This is non-negotiable. PDs scan sections quickly. A mixed list forces them to investigate each entry, which breeds suspicion.
Rule 3: State the submission status explicitly. Format example: "Smith J, Doe A. Title of Paper. medRxiv. 2024. DOI: 10.1101/2024.xx.xx.xxxx. Submitted to Journal of Cardiology, under review as of September 2024." The status update signals that you're actively pursuing peer review, not hiding from it.
Rule 4: Do not list withdrawn or substantially revised preprints without updating them. If you posted Version 1 with flawed methods and never posted Version 2, that Version 1 is a liability. Either update the preprint server with a revised version or remove it from your CV.
Rule 5: Order matters. Peer-reviewed publications come first, always. Preprints come after. Within preprints, order by date or perceived impact, whichever favors you.
Rule 6: Don't pad. One preprint in a research-heavy specialty looks like early productivity. Four preprints with zero peer-reviewed work looks like you're trying to manufacture a research profile. Quality and execution beat volume.
Specialty-Specific Calibration
A quick calibration matrix, because context matters:
- Dermatology, plastic surgery, orthopaedic surgery, neurosurgery: Lean toward listing only if peer-reviewed work is sparse. These specialties weight peer review heavily.
- Internal medicine, pediatrics, radiology, radiation oncology: Preprints are generally well-tolerated, especially in research-track programs.
- Family medicine, community psychiatry, Med-Peds: Listing is lower-stakes but still requires proper formatting.
- Academic-track prelim/transitional years: Listing is essentially expected if you have any research at all.
The Verdict Depends on Context and Execution
Here's the bottom line: preprints are not inherently bad, but careless listing will absolutely backfire. The evidence supports a nuanced position, they're a neutral-to-mildly-positive signal when formatted correctly, a clear negative when they're not.
Your job is to assess three things: your specialty's norms, your timeline relative to ERAS opening, and the quality of the actual preprint. If your preprint is methodologically tight, posted on a recognized server, and clearly labeled, list it. If it's a mess, or you're hiding it inside a peer-reviewed section, don't.
Apply the decision flowchart. Talk to your research mentor and a recent match from your target specialty. Then make the call and execute it cleanly.
The myth worth busting one last time: there is no "right" answer in the abstract. There's only the right answer for your application, in your specialty, with your specific preprint. Build that judgment. Don't outsource it to a forum post.
